Explore this article's sources with AI
Follow PeptideMethods on Google
Incretin Drugs for PCOS: 2026 Review
A 2026 review maps semaglutide, tirzepatide and retatrutide for PCOS, but reproductive evidence still trails weight-loss data.
Why we wrote this. Pipeline reviews can sound more mature than the evidence. We mapped the drug classes and kept reproductive claims bounded.
In this article (4 sections)
A 2026 narrative review argues that incretin medicines may improve the metabolic features that often accompany polycystic ovary syndrome, or PCOS. The paper uses the newer term polyendocrine metabolic ovarian syndrome. Its main caution matters more than the pipeline list: evidence for reproductive outcomes is limited, especially for tirzepatide and investigational retatrutide. No new participants were enrolled, and the review does not establish that multi-incretin drugs improve fertility or pregnancy outcomes[1].
What the review covered
The authors searched PubMed for work published from January 2023 to October 2026, then added ClinicalTrials.gov records and papers found in reference lists. They evaluated metabolic and hormonal outcomes alongside reproductive measures. The review follows a drug-development sequence from single GLP-1 receptor agonists, including semaglutide, to the dual GIP and GLP-1 receptor agonist tirzepatide and retatrutide, which targets those two pathways plus glucagon receptors[1].
That structure should not be mistaken for a head-to-head comparison. Narrative reviews can organize an emerging field, but they do not pool results under a prespecified statistical model. The abstract reports a structured search, yet the indexed record does not provide the full study-by-study selection data needed to reproduce every inclusion decision. Retatrutide also remains an investigational medicine, and the review does not report a PCOS-specific randomized retatrutide trial[1].
Where the evidence is strongest
The review describes the clearest evidence as metabolic. Single GLP-1 receptor agonists, particularly semaglutide, can reduce weight and adiposity and improve measures of insulin resistance. It says evidence of reproductive benefit is emerging, not settled. Multi-incretin drugs may produce larger changes in body weight, visceral fat, ectopic fat, and insulin resistance, but a larger metabolic effect does not automatically prove a direct ovarian or fertility effect[1].
A small 2023 primary study shows why the distinction matters. It followed 27 women with obesity and PCOS who had lost less than 5% of body weight during a prior lifestyle program. All had phenotype A PCOS under Rotterdam criteria. After three months of semaglutide, the authors reported a mean weight reduction of 7.6 kg, and almost 80% lost at least 5% of body weight. This was an uncontrolled cohort, not a randomized placebo comparison[2].
Responders in that cohort continued treatment for another three months. Their mean weight loss reached 11.5 kg, and the paper reported normalized menstrual cycles in 80% of responders. That responder-only follow-up creates selection bias. It cannot show that semaglutide caused cycle normalization independently of weight loss, nor can it tell us how untreated participants would have changed over the same period[2].
What is missing for tirzepatide and retatrutide
Tirzepatide has strong evidence for weight and glycaemic outcomes in its approved populations, but the review says PMOS-specific reproductive evidence remains limited. Retatrutide sits another step back because it is still in clinical development. Results from general obesity trials can justify research interest, but they cannot answer whether ovulation, androgen measures, menstrual regularity, fertility, or pregnancy outcomes improve in a defined PCOS population[1].
The molecules also should not be treated as interchangeable. Semaglutide targets the GLP-1 receptor. Tirzepatide targets GIP and GLP-1 receptors. Retatrutide adds glucagon receptor agonism. Different receptor profiles and different trial populations mean that a result for one drug cannot simply be assigned to the others. Their approval status also differs by market, which readers can check in our regulation library.
A useful future trial would enroll participants by a stated PCOS phenotype before randomization, record baseline weight and metabolic status, and define reproductive outcomes in advance. It would keep outcome reporting consistent across groups and follow participants after treatment withdrawal. That design could test whether cycle or ovulation changes track only with weight change, whether any benefit persists, and whether adverse effects differ for people planning pregnancy. Without those controls, promising metabolic observations remain difficult to translate into a reproductive claim. The review's call for standardized endpoints is therefore a methods issue, not a minor reporting preference[1].
What we do not know
The review identifies three central uncertainties. Researchers do not know whether reproductive changes are independent of weight loss, whether benefits persist after treatment stops, or whether effects differ across PCOS phenotypes. The field also lacks phenotype-stratified randomized trials with standardized reproductive, metabolic, cardiovascular, and safety endpoints. Those gaps make it hard to compare studies or decide whether a metabolic improvement translates into a durable reproductive benefit[1].
Pregnancy planning adds another evidence boundary. Weight change before conception, menstrual regularity, ovulation, conception, live birth, and maternal or infant safety are separate outcomes. A study that reports one cannot stand in for all the others. The 2023 semaglutide cohort did not include a randomized control group and was not designed to establish pregnancy safety. The 2026 review calls for reproductive safety and access to remain part of future trial design[1][2].
This review supports a research agenda, not a treatment ranking. People with PCOS differ in metabolic risk, reproductive goals, other medicines, and contraindications. Incretin medicines are prescription treatments, and retatrutide is investigational. Anyone considering treatment should discuss the approved options and pregnancy plans with a qualified clinician. A review of an emerging pipeline cannot replace individualized care.
Frequently asked
Did this review include a new PCOS clinical trial?
No. It was a narrative review of published studies, trial registry records, and reference lists. It enrolled no new participants.
Does semaglutide improve menstrual cycles in PCOS?
A small uncontrolled 2023 cohort reported cycle normalization in many semaglutide responders, but the design cannot separate a drug effect from weight loss, time, or selection of responders.
Has tirzepatide been proven to improve fertility in PCOS?
No. The 2026 review says PCOS-specific reproductive evidence remains limited. Weight-loss and metabolic results from other populations do not prove fertility benefit.
Is retatrutide approved for PCOS?
No. Retatrutide remains investigational and is not approved for PCOS. The review discusses it as a future research candidate, not an established treatment.
Sources
No revisions yet. First published .